Journal of visualized experiments : JoVEfms-Like Tyrosine Kinase 3LeukemiaMyeloidAcuteHumans
Canertinib as an FLT3 Inhibitor with Potent Activity Against FLT3-Mutated and AC220-Resistant Acute Myeloid Leukemia.
Hongfeng Pang, Chaoling Wan, Maofeng Zhang, Shuaishuai Ge, Yuanhong Huang, Chengqiao Qiu, Shengli Xue, Depei Wu, Songbai Liu
Published: 202510.3791/69655
Abstract
FMS-like tyrosine kinase 3 (FLT3) mutations are among the most common genetic lesions in acute myeloid leukemia (AML) and are frequently associated with high relapse rates and poor prognosis. Although current FLT3 inhibitors have improved outcomes, a…
Preview only. Read the full abstract at the source